A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Summary

The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alzheimer Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

50 to 85 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Eli Lilly and Company

Last updated on ClinicalTrials.gov

August 24, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites